Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients

被引:4
|
作者
Naicker, Derisha [1 ]
Reed, Peter W. [2 ]
Ronaldson, Jane [1 ]
Kara, Tonya [1 ]
Wong, William [1 ]
Prestidge, Chanel [1 ]
机构
[1] Starship Childrens Hosp, Dept Pediat Nephrol, Pk Rd,Private Bag 92024, Auckland 1142, New Zealand
[2] Starship Childrens Hosp, Childrens Res Ctr, Auckland, New Zealand
关键词
Calcineurin inhibitor; Generic Immunosuppression; Renal; Tacrolimus; Transplantation; IMMUNOSUPPRESSION; PROGRAF; DRUGS;
D O I
10.1007/s00467-017-3707-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Bioequivalence between Tacrolimus Prograf (R) and generic tacrolimus formulations has been demonstrated in adult populations,however clinical experience and safety data regarding generic tacrolimus in pediatric transplant recipients is limited. This study aimed to evaluate conversion from Tacrolimus Prograf (R) to Sandoz (R) in pediatric renal transplant recipients nationwide. The primary outcome was a change in mean trough tacrolimus concentration. Additionally, changes in tacrolimus intra-patient coefficient of variation (CoV), allograft function, requirement for dose adjustments, and episodes of biopsy-proven rejection were evaluated. Methods Retrospective cohort study in 37 pediatric renal transplant recipients who switched to Tacrolimus Sandoz (R). Each patient had three pre-conversion tacrolimus trough and creatinine concentrations within the 4 months prior and three post-conversion concentrations on day 3, 10, and the next subsequent level. Mean pre-and post-conversion tacrolimus trough concentrations and glomerular filtration rate (eGFR) were calculated. Tacrolimus concentration, CoV, and creatinine differences were compared by paired t test. Results Thirty-seven patients (41% females, age 3-18 years) were included. Average intra-patient difference in trough tacrolimus concentration was 0.05 mu g/l (95% CI -0.37 to 0.47). Average intra-patient difference in eGFR was -1.20 ml/min/1.73(2) (95% CI -3.53 to 1.13). Three patients had acute rejection during 12 months post-conversion compared to none during 12 months pre-conversion. Conclusions Pediatric renal transplant recipients can be converted from Tacrolimus Prograf (R) to Sandoz (R) with negligible change in trough concentration, dose adjustments, or immediate allograft function. Of concern was the number of acute rejection episodes, however non-adherence contributed to at least one episode and this difference was determined clinically and statistically not significant.
引用
收藏
页码:2125 / 2131
页数:7
相关论文
共 50 条
  • [21] Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients
    Wu, Sheng-Wen
    Tsai, Hui-Ching
    Tsai, Pao-Yu
    Hung, Tung-Wei
    Chang, Horng-Rong
    Lian, Jong-Da
    SWISS MEDICAL WEEKLY, 2013, 143
  • [22] Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy
    Tang, Sydney Chi-Wai
    Chan, Kwok Wah
    Tang, Colin Siu-On
    Lam, Man Fai
    Leung, Chung Ying
    Tse, Kai Chung
    Li, Chun Sang
    Ho, Yiu Wing
    Tong, Matthew Kwok-Lung
    Lai, Kar Neng
    Chan, Tak Mao
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (11) : 3243 - 3251
  • [23] Estimation of a Tacrolimus to Sirolimus Dose Conversion Ratio in Kidney Transplant Recipients
    Kim, M.
    Mandelbrot, D.
    Rogers, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 303 - 304
  • [24] Alemtuzumab preconditioning and tacrolimus monotherapy in pediatric kidney transplant recipients.
    Shapiro, Ron
    Ellis, Demetrius
    Tan, Henkie P.
    Moritz, Michael L.
    Basu, Amit
    Vats, Abhay N.
    Kayler, Liise K.
    Erkan, Elif
    McFeaters, Corde G.
    James, Gerri
    Grosso, Mary J.
    Zeevi, Adriana
    Gray, Edward A.
    Marcos, Amadeo
    Starzl, Thomas E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 188 - 188
  • [25] Alemtuzumab preconditioning and tacrolimus monotherapy in pediatric kidney transplant recipients.
    Shapiro, Ron
    El Jis, Demetrius
    Tan, Henkie P.
    Tz, Michael L. Mori
    Basu, Amit
    Vats, AbhayN.
    Kayler, Liise K.
    Erkan, Elif
    McFeaters, Corde G.
    James, Gerri
    Grosso, Mary J.
    Zeevi, Adriana
    Gray, Edward A.
    Marcos, Amadeo
    Starzl, Thomas E.
    PEDIATRIC TRANSPLANTATION, 2007, 11 : 54 - 54
  • [26] Blood pressure in pediatric kidney transplant recipients treated with tacrolimus.
    Aviles, DH
    Boudreaux, JP
    Frey, DJ
    Irwin, KC
    Vehaskari, VM
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (01) : 20A - 20A
  • [27] RELATIONSHIP OF QTc INTERVAL TO TACROLIMUS LEVEL IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
    Goldberg, Aviva M.
    Birk, Patricia E.
    Buffo, Ilan
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 130 - 130
  • [28] Conversion of Tacrolimus Immediate Release to LCP-Tacrolimus in Non-Kidney Transplant Recipients
    Lucarelli, S. E.
    Le, T.
    Lichvar, A.
    Kerr, J.
    Kozuch, J.
    Tsunoda, S.
    Feist, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S581 - S582
  • [29] Clinical Outcomes of Inadvertent Conversion from Brand to Generic Tacrolimus in Renal Transplant Recipients
    Marfo, K.
    Akalin, E.
    Daniel, G.
    de Boccardo, G.
    Aitken, S.
    Jones, T.
    Lu, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 507 - 507
  • [30] Tacrolimus pharmacokinetics in kidney transplant recipients
    Ravera, Federica
    Cappelli, Gianni
    Bonucchi, Decenzio
    Davoli, Delia
    Rubbiani, Elisabetta
    Savazzi, Anna Maria
    Pini, Luigi Alberto
    Albertazzi, Alberto
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 271 - 272